Year All20262025202420232022202120202019 Aug 12, 2026 Aligos Therapeutics Announces First Participant Dosed in the Phase 1 Study of its Potentially Best-in-Class Antisense Oligonucleotide ALG-170675 by its Partner Amoytop in China Aug 06, 2026 Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results Jul 30, 2026 Aligos Therapeutics to Announce 2nd Quarter 2026 Financial Results on August 6, 2026 Jul 13, 2026 Aligos Therapeutics Announces the Completion of Enrollment in the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium Under Development for the Treatment of Chronic HBV Infection Jul 06, 2026 Aligos Therapeutics Receives Upfront Payment of $25M USD from the Exclusive License Deal of Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection May 27, 2026 Aligos Therapeutics Presents Positive Data at the EASL Congress 2026 May 13, 2026 Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at the EASL Congress 2026 May 07, 2026 Aligos Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results Apr 30, 2026 Aligos Therapeutics to Announce 1st Quarter 2026 Financial Results on May 7, 2026 Apr 24, 2026 Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 12, 2026 Aligos Therapeutics Announces First Participant Dosed in the Phase 1 Study of its Potentially Best-in-Class Antisense Oligonucleotide ALG-170675 by its Partner Amoytop in China
Aug 06, 2026 Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results
Jul 13, 2026 Aligos Therapeutics Announces the Completion of Enrollment in the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium Under Development for the Treatment of Chronic HBV Infection
Jul 06, 2026 Aligos Therapeutics Receives Upfront Payment of $25M USD from the Exclusive License Deal of Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection
May 13, 2026 Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at the EASL Congress 2026
May 07, 2026 Aligos Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results
